Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Vor Biopharma Inc
(NQ:
VOR
)
0.9700
+0.0161 (+1.69%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
755,467
Open
0.9500
Bid (Size)
0.9325 (30)
Ask (Size)
0.9700 (13)
Prev. Close
0.9539
Today's Range
0.8534 - 0.9976
52wk Range
0.7000 - 3.140
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
VOR Stock Earnings: Vor Biopharma Beats EPS for Q2 2024
August 09, 2024
VOR stock results show that Vor Biopharma beat analyst estimates for earnings per share the second quarter of 2024.
Via
InvestorPlace
Vor Bio Reports Second Quarter 2024 Financial Results and Provides Company Update
August 08, 2024
From
Vor Biopharma
Via
GlobeNewswire
Performance
YTD
-56.50%
-56.50%
1 Month
N/A
N/A
3 Month
-35.76%
-35.76%
6 Month
-51.13%
-51.13%
1 Year
-63.26%
-63.26%
More News
Read More
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
August 02, 2024
From
Vor Biopharma
Via
GlobeNewswire
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
July 09, 2024
From
Vor Biopharma
Via
GlobeNewswire
Vor Biopharma: Q4 Earnings Insights
March 20, 2024
Via
Benzinga
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
June 04, 2024
From
Vor Biopharma
Via
GlobeNewswire
VOR Stock Earnings: Vor Biopharma Beats EPS for Q1 2024
May 09, 2024
Via
InvestorPlace
Vor Bio Reports First Quarter 2024 Financial Results and Provides Company Update
May 09, 2024
From
Vor Biopharma
Via
GlobeNewswire
Vor Bio to Participate in Upcoming Investor Conferences
May 06, 2024
From
Vor Biopharma
Via
GlobeNewswire
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
May 03, 2024
From
Vor Biopharma
Via
GlobeNewswire
Vor Bio Appoints Accomplished Oncology and Cancer Immunotherapy R&D Executive, Fouad Namouni, M.D., to its Board of Directors
May 02, 2024
From
Vor Biopharma
Via
GlobeNewswire
12 Health Care Stocks Moving In Friday's After-Market Session
April 05, 2024
Via
Benzinga
Vor Bio to Participate in Upcoming Investor Conferences
April 01, 2024
From
Vor Biopharma
Via
GlobeNewswire
The Penny Stock A-List: 7 High-Profile Companies on the Verge of Greatness
March 28, 2024
Via
InvestorPlace
VOR Stock Earnings: Vor Biopharma Beats EPS for Q4 2023
March 20, 2024
Via
InvestorPlace
Vor Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update
March 20, 2024
From
Vor Biopharma
Via
GlobeNewswire
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
March 05, 2024
From
Vor Biopharma
Via
GlobeNewswire
Vor Bio to Participate in Upcoming Investor Conferences
March 04, 2024
From
Vor Biopharma
Via
GlobeNewswire
Vor Bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
February 07, 2024
From
Vor Biopharma
Via
GlobeNewswire
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
February 02, 2024
From
Vor Biopharma
Via
GlobeNewswire
Vor Bio Doses First AML Patient with VCAR33 (ALLO) and Provides Corporate Update
January 17, 2024
From
Vor Biopharma
Via
GlobeNewswire
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
December 21, 2023
From
Vor Biopharma
Via
GlobeNewswire
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
December 01, 2023
From
Vor Biopharma
Via
GlobeNewswire
Vor Bio to Participate in the JMP Securities Hematology and Oncology Summit
November 27, 2023
From
Vor Biopharma
Via
GlobeNewswire
Vor Bio Presents Positive Data Update on Trem-cel at HSCT² Conference
November 09, 2023
From
Vor Biopharma
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.